Andrew Slee
Geschäftsführer bei PROTAGENIC THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Profil
Andrew Slee is the founder of Vivisource Laboratories, Inc. (founded in 2003).
He is currently the Chief Operating Officer at Protagenic Therapeutics, Inc. (since 2016).
Dr. Slee previously worked as the Senior Director-Preclinical Pharmacology at Safety Pharmacology Society, Principal at DuPont Pharmaceuticals Co., Principal at DuPont Merck Pharmaceutical Co., Vice President-Pharmacology at Enanta Pharmaceuticals, Inc., and Vice President-Pharmacology & Development at SelectX Pharmaceuticals, Inc. (from 2000 to 2012).
He completed his undergraduate degree at Syracuse University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Andrew Slee
| Unternehmen | Position | Beginn |
|---|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Geschäftsführer | 01.04.2016 |
Ehemalige bekannte Positionen von Andrew Slee
| Unternehmen | Position | Ende |
|---|---|---|
| Vivisource Laboratories, Inc. | Gründer | 01.10.2013 |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| ENANTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Corporate Officer/Principal | - |
Ausbildung von Andrew Slee
| Syracuse University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
| Vivisource Laboratories, Inc. | |
| Safety Pharmacology Society |
